Literature DB >> 16527321

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.

Rong Xu1, Indresh K Srivastava, Larene Kuller, Irina Zarkikh, Zane Kraft, Zahra Fagrouch, Norman L Letvin, Jonathan L Heeney, Susan W Barnett, Leonidas Stamatatos.   

Abstract

Immunization by the SF162gp140 or the DeltaV2gp140 HIV-1 envelope proteins results in the generation of strong homologous neutralizing antibodies (NAbs) that offer similar degree of protection from disease-development to macaques challenged with homologous virus. These two immunogens elicit weak cross-reactive NAbs and their effectiveness against heterologous challenge is currently unknown. To examine this issue, we immunized macaques with SIVGag p55 and either the SF162gp140 or the DeltaV2gp140 and challenged them intravenously with SHIV-89.6P. All animals became infected but previous immunization with SF162gp140 accelerated the development of anti-SHIV89.6P neutralizing antibody responses following infection. DeltaV2gp140 is derived from SF162gp140 following the deletion of 30 amino acids and one N-linked glycosylation site from the V2 loop. Our results suggest that even small differences in HIV Envelope immunogen structure can affect the neutralizing antibody responses generated following infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527321     DOI: 10.1016/j.virol.2006.01.043

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

2.  Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Authors:  Nina R Derby; Sean Gray; Elizabeth Wayner; Dwayne Campogan; Giorgos Vlahogiannis; Zane Kraft; Susan W Barnett; Indresh K Srivastava; Leonidas Stamatatos
Journal:  Virology       Date:  2007-06-08       Impact factor: 3.616

3.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

4.  Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Authors:  Robert J O'Connell; Jean-Louis Excler; Victoria R Polonis; Silvia Ratto-Kim; Josephine Cox; Linda L Jagodzinski; Michelle Liu; Lindsay Wieczorek; John G McNeil; Raphaelle El-Habib; Nelson L Michael; Bruce L Gilliam; Robert Paris; Thomas C VanCott; Georgia D Tomaras; Deborah L Birx; Merlin L Robb; Jerome H Kim
Journal:  J Infect Dis       Date:  2016-02-11       Impact factor: 5.226

5.  Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic.

Authors:  Grégoire Martin; Brian Burke; Robert Thaï; Antu K Dey; Olivier Combes; Oscar H P Ramos; Bernadette Heyd; Anthony R Geonnotti; David C Montefiori; Elaine Kan; Ying Lian; Yide Sun; Toufik Abache; Jeffrey B Ulmer; Hocine Madaoui; Raphaël Guérois; Susan W Barnett; Indresh K Srivastava; Pascal Kessler; Loïc Martin
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

Review 6.  Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Authors:  George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

7.  A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.

Authors:  For Yue Tso; Federico G Hoffmann; Damien C Tully; Philippe Lemey; Robert A Rasmussen; Hong Zhang; Ruth M Ruprecht; Charles Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

Review 8.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

9.  Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.

Authors:  Patricia Polacino; Kay Larsen; Lindsey Galmin; John Suschak; Zane Kraft; Leonidas Stamatatos; David Anderson; Susan W Barnett; Ranajit Pal; Kristen Bost; A H Bandivdekar; Christopher J Miller; Shiu-Lok Hu
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

10.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.